Janus Kinase Inhibitors
- Name
- Janus Kinase Inhibitors
- Accession Number
- DBCAT004108
- Description
Agents that inhibit JANUS KINASES.
- Drugs
Drug Drug Description Tofacitinib A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis. Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. Upadacitinib An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. Abrocitinib A kinase inhibitor used to treat moderate-to-severe atopic dermatitis in adults. Deucravacitinib A TYK2 inhibitor being investigated as a treatment for psoriasis. Ritlecitinib A kinase inhibitor used to treat severe alopecia areata in adults and adolescents 12 years and older. - Drugs & Drug Targets